Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency

被引:3
作者
Davidson, Simon J. [1 ]
Turner, Natalie [1 ]
Tillyer, Louise [1 ]
机构
[1] Royal Brompton Hosp, Dept Haematol, London SW3 6LY, England
关键词
anticoagulation; factor VII deficiency; hypertrophic cardiomyopathy; INTERNATIONAL-NORMALIZED-RATIO; THROMBIN GENERATION; COAGULATION DISORDERS; WARFARIN; THERAPY; PLASMA;
D O I
10.1097/MBC.0b013e32833e47ad
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 50-year-old male patient with hypertrophic cardiomyopathy and atrial fibrillation was anticoagulated, with warfarin following insertion of a cardioverter defibrillator. He became markedly over anticoagulated after standard moderate induction doses of warfarin. His baseline prothrombin time was prolonged and further investigation showed the patient to have a mild factor VII deficiency. He was restarted on low-dose warfarin and successfully stabilized with a target international normalized ratio (INR) of 3.0 (range 2.5-3.5). We used the data from factor VII levels and thrombin generation studies before and after anticoagulation to control dosage and to decide on a suitable therapeutic range for the INR. Molecular studies showed him to have two separate mutations in the factor VII gene. This report highlights the importance of noting the baseline prothrombin time before initiating oral anticoagulation and describes how well tolerated anticoagulation can be achieved in a patient with congenital factor VII deficiency. Blood Coagul Fibrinolysis 21: 707-708 (c) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:707 / 708
页数:2
相关论文
共 15 条
[1]   The thrombogram in rare inherited coagulation disorders:: Its relation to clinical bleeding [J].
Al Dieri, R ;
Peyvandi, F ;
Santagostino, E ;
Giansily, M ;
Mannucci, PM ;
Schved, JF ;
Béguin, S ;
Hemker, HC .
THROMBOSIS AND HAEMOSTASIS, 2002, 88 (04) :576-582
[2]   Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy [J].
Altman, R. ;
Scazziota, A. ;
Herrera, L. ;
Gonzalez, C. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (07) :1552-1554
[3]  
ARBINI AA, 1994, BLOOD, V84, P2214
[4]   The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation [J].
Bolton-Maggs, PHB ;
Perry, DJ ;
Chalmers, EA ;
Parapia, LA ;
Wilde, JT ;
Williams, MD ;
Collins, PW ;
Kitchen, S ;
Dolan, G ;
Mumford, AD .
HAEMOPHILIA, 2004, 10 (05) :593-628
[5]   Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio [J].
Christensen, Thomas D. ;
Jensen, Claus ;
Larsen, Torben B. ;
Christiansen, Kirsten ;
Sorensen, Benny .
BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (05) :358-365
[6]   Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy [J].
Costa, I. M. ;
Serralheiro, A. I. ;
Rodrigues, M. ;
Alves, G. ;
Falcao, A. C. .
BIOMEDICINE & PHARMACOTHERAPY, 2010, 64 (02) :130-132
[7]   Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation [J].
Gatt, A. ;
van Veen, J. J. ;
Bowyer, A. ;
Woolley, A. M. ;
Cooper, P. ;
Kitchen, S. ;
Makris, M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (06) :946-952
[8]  
GIROLAMI A, 1978, J LAB CLIN MED, V91, P387
[9]   A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy [J].
Jackson, CM ;
Esnouf, MP ;
Lindahl, TL .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) :43-51
[10]  
KITCHEN S, 1992, THROMB HAEMOSTASIS, V68, P301